News
1d
AZoLifeSciences on MSNStudy Reveals T Cell Plasticity as a Key Driver of Systemic AutoimmunityAfter spending years tracing the origin and migration pattern of an unusual type of immune cell in mice, researchers have ...
The transition from preclinical development to clinical trials is a critical, with approximately 89% of drugs failing. Nearly half of these failures stem from unexpected and unmanageable human ...
U S health secretary Robert F Kennedy Jr has recently made a pretty bold – and misleading – claim about the measles, mumps, and rubella (MMR) vaccine, stating that it contains “a lot of aborted fetus ...
IO Biotech's first-in-class vaccine performs double duty, killing cancer cells and enhancing the tumor microenvironment. A ...
NIH program to make vaccines against pathogens that can trigger pandemics uses approach pioneered in last century ...
Email mistake reveals secret plans to end research on Head Start and other child safety net programs
A Department of Health and Human Services employee has emailed dozens of people this week, mistakenly including plans to ...
Though hiring has slowed from its frantic pace a few years ago, companies still need to fill critical positions in ...
U.S. health secretary Robert F. Kennedy Jr. reprised various misleading claims about vaccines this week, including that the ...
The US Department of Health and Human Services said Thursday that it aims to accomplish within four years a scientific feat ...
A specialized model used by researchers is becoming a valuable tool for studying human brain development, diseases and ...
Bempikibart (ADX-914) is a human anti-IL-7Rα antibody that blocks the IL-7 and TSLP pathways, which have been implicated in driving T cell-mediated pathological processes in autoimmune diseases.
“This is a clear and deliberate shift,” Corbett says.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results